Arkuda Reels in Another $64M to Disrupt Neurodegenerative Disease Treatment
Arkuda seeks to disrupt the usual progression of neurodegenerative disease with medicines developed by applying cutting-edge knowledge from the domains of lysosomal and microglial biology.